Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 110

Similar articles for PubMed (Select 22416102)

1.

Association of age at diagnosis and genetic mutations in patients with neuroblastoma.

Cheung NK, Zhang J, Lu C, Parker M, Bahrami A, Tickoo SK, Heguy A, Pappo AS, Federico S, Dalton J, Cheung IY, Ding L, Fulton R, Wang J, Chen X, Becksfort J, Wu J, Billups CA, Ellison D, Mardis ER, Wilson RK, Downing JR, Dyer MA; St Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project.

JAMA. 2012 Mar 14;307(10):1062-71. doi: 10.1001/jama.2012.228.

2.

Whole-exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas.

Fishbein L, Khare S, Wubbenhorst B, DeSloover D, D'Andrea K, Merrill S, Cho NW, Greenberg RA, Else T, Montone K, LiVolsi V, Fraker D, Daber R, Cohen DL, Nathanson KL.

Nat Commun. 2015 Jan 21;6:6140. doi: 10.1038/ncomms7140.

PMID:
25608029
3.

Clinical features of ATRX or DAXX mutated neuroblastoma.

Kurihara S, Hiyama E, Onitake Y, Yamaoka E, Hiyama K.

J Pediatr Surg. 2014 Dec;49(12):1835-8. doi: 10.1016/j.jpedsurg.2014.09.029. Epub 2014 Nov 14.

PMID:
25487495
4.

Leiomyosarcoma with alternative lengthening of telomeres is associated with aggressive histologic features, loss of ATRX expression, and poor clinical outcome.

Liau JY, Tsai JH, Jeng YM, Lee JC, Hsu HH, Yang CY.

Am J Surg Pathol. 2015 Feb;39(2):236-44. doi: 10.1097/PAS.0000000000000324.

PMID:
25229770
5.

Platform comparison for evaluation of ALK protein immunohistochemical expression, genomic copy number and hotspot mutation status in neuroblastomas.

Yan B, Kuick CH, Lim M, Venkataraman K, Tennakoon C, Loh E, Lian D, Leong MY, Lakshmanan M, Tergaonkar V, Sung WK, Soh SY, Chang KT.

PLoS One. 2014 Sep 4;9(9):e106575. doi: 10.1371/journal.pone.0106575. eCollection 2014.

6.

Neuroblastoma after childhood: prognostic relevance of segmental chromosome aberrations, ATRX protein status, and immune cell infiltration.

Berbegall AP, Villamón E, Tadeo I, Martinsson T, Cañete A, Castel V, Navarro S, Noguera R.

Neoplasia. 2014 Jun;16(6):471-80. doi: 10.1016/j.neo.2014.05.012.

7.

Emergence of new ALK mutations at relapse of neuroblastoma.

Schleiermacher G, Javanmardi N, Bernard V, Leroy Q, Cappo J, Rio Frio T, Pierron G, Lapouble E, Combaret V, Speleman F, de Wilde B, Djos A, Ora I, Hedborg F, Träger C, Holmqvist BM, Abrahamsson J, Peuchmaur M, Michon J, Janoueix-Lerosey I, Kogner P, Delattre O, Martinsson T.

J Clin Oncol. 2014 Sep 1;32(25):2727-34. doi: 10.1200/JCO.2013.54.0674. Epub 2014 Jul 28.

PMID:
25071110
9.

Oncogenic PTPN11 mutations are rare in solid tumors.

Je EM, Choi YJ, Yoo NJ, Lee SH.

Pathol Oncol Res. 2015 Jan;21(1):225-7. doi: 10.1007/s12253-014-9780-z. Epub 2014 Apr 26. No abstract available.

PMID:
24771269
10.

Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma.

Chen X, Bahrami A, Pappo A, Easton J, Dalton J, Hedlund E, Ellison D, Shurtleff S, Wu G, Wei L, Parker M, Rusch M, Nagahawatte P, Wu J, Mao S, Boggs K, Mulder H, Yergeau D, Lu C, Ding L, Edmonson M, Qu C, Wang J, Li Y, Navid F, Daw NC, Mardis ER, Wilson RK, Downing JR, Zhang J, Dyer MA; St. Jude Children’s Research Hospital–Washington University Pediatric Cancer Genome Project.

Cell Rep. 2014 Apr 10;7(1):104-12. doi: 10.1016/j.celrep.2014.03.003. Epub 2014 Apr 3.

11.

Neuroblastoma mRNAs predict outcome in children with stage 4 neuroblastoma: a European HR-NBL1/SIOPEN study.

Viprey VF, Gregory WM, Corrias MV, Tchirkov A, Swerts K, Vicha A, Dallorso S, Brock P, Luksch R, Valteau-Couanet D, Papadakis V, Laureys G, Pearson AD, Ladenstein R, Burchill SA.

J Clin Oncol. 2014 Apr 1;32(10):1074-83. doi: 10.1200/JCO.2013.53.3604. Epub 2014 Mar 3.

12.

SPOP mutations in prostate cancer across demographically diverse patient cohorts.

Blattner M, Lee DJ, O'Reilly C, Park K, MacDonald TY, Khani F, Turner KR, Chiu YL, Wild PJ, Dolgalev I, Heguy A, Sboner A, Ramazangolu S, Hieronymus H, Sawyers C, Tewari AK, Moch H, Yoon GS, Known YC, Andrén O, Fall K, Demichelis F, Mosquera JM, Robinson BD, Barbieri CE, Rubin MA.

Neoplasia. 2014 Jan;16(1):14-20.

13.

Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors.

Marinoni I, Kurrer AS, Vassella E, Dettmer M, Rudolph T, Banz V, Hunger F, Pasquinelli S, Speel EJ, Perren A.

Gastroenterology. 2014 Feb;146(2):453-60.e5. doi: 10.1053/j.gastro.2013.10.020. Epub 2013 Oct 19.

PMID:
24148618
14.

Massively parallel sequencing reveals an accumulation of de novo mutations and an activating mutation of LPAR1 in a patient with metastatic neuroblastoma.

Wei JS, Johansson P, Chen L, Song YK, Tolman C, Li S, Hurd L, Patidar R, Wen X, Badgett TC, Cheuk AT, Marshall JC, Steeg PS, Vaqué Díez JP, Yu Y, Gutkind JS, Khan J.

PLoS One. 2013 Oct 16;8(10):e77731. doi: 10.1371/journal.pone.0077731. eCollection 2013.

15.

Neuroblastoma in older children, adolescents and young adults: a report from the International Neuroblastoma Risk Group project.

Mossé YP, Deyell RJ, Berthold F, Nagakawara A, Ambros PF, Monclair T, Cohn SL, Pearson AD, London WB, Matthay KK.

Pediatr Blood Cancer. 2014 Apr;61(4):627-35. doi: 10.1002/pbc.24777. Epub 2013 Sep 13.

PMID:
24038992
16.

ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis.

Wiestler B, Capper D, Holland-Letz T, Korshunov A, von Deimling A, Pfister SM, Platten M, Weller M, Wick W.

Acta Neuropathol. 2013 Sep;126(3):443-51. doi: 10.1007/s00401-013-1156-z. Epub 2013 Aug 1.

PMID:
23904111
17.

The alternative lengthening of telomere phenotype is significantly associated with loss of ATRX expression in high-grade pediatric and adult astrocytomas: a multi-institutional study of 214 astrocytomas.

Abedalthagafi M, Phillips JJ, Kim GE, Mueller S, Haas-Kogen DA, Marshall RE, Croul SE, Santi MR, Cheng J, Zhou S, Sullivan LM, Martinez-Lage M, Judkins AR, Perry A.

Mod Pathol. 2013 Nov;26(11):1425-32. doi: 10.1038/modpathol.2013.90. Epub 2013 Jun 14.

18.

Neuroblastoma: developmental biology, cancer genomics and immunotherapy.

Cheung NK, Dyer MA.

Nat Rev Cancer. 2013 Jun;13(6):397-411. doi: 10.1038/nrc3526. Review.

19.

Age dependence of tumor genetics in unfavorable neuroblastoma: arrayCGH profiles of 34 consecutive cases, using a Swedish 25-year neuroblastoma cohort for validation.

Cetinkaya C, Martinsson T, Sandgren J, Träger C, Kogner P, Dumanski J, Díaz de Ståhl T, Hedborg F.

BMC Cancer. 2013 May 9;13:231. doi: 10.1186/1471-2407-13-231.

20.

High incidence of MYCN amplification in a Moroccan series of neuroblastic tumors: comparison to current biological data.

Tabyaoui I, Tahiri-Jouti N, Serhier Z, El Maani K, Cherkaoui S, Al Zemmouri M, Othmani MB, Zamiati S.

Diagn Mol Pathol. 2013 Jun;22(2):112-8. doi: 10.1097/PDM.0b013e318277448e.

PMID:
23628823
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk